Pfizer Inc. (PFE)
UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant
Britain's health regulator said on Wednesday it has authorised Pfizer and BioNTech's updated COVID-19 vaccine that targets the JN.1 subvariant of the coronavirus for use in infants, children and adults.
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Sangamo Therapeutics Inc SGMO, which developed a treatment in collaboration with Pfizer Inc PFE, received a boost to its stock price after struggling with liquidity issues.
Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do?
Pfizer ( PFE) will report its second-quarter 2024 earnings on Jul 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.22 billion and 45 cents per share, respectively.
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
Pfizer is developing danuglipron -- a once-daily weight loss drug. In studies of a twice-daily version, some trial participants lost more than 10% of their body weight.
Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
Pfizer said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. The hemophilia A treatment could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.
Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial
Pfizer said on Wednesday that its gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment.
Earnings Preview: Pfizer (PFE) Q2 Earnings Expected to Decline
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
Pfizer and Roche don't have any anti-obesity medicines marketed yet. Both are trying to change that as fast as possible.
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
Pfizer doesn't currently produce any anti-obesity medicines, but it wants to do so. However, its most mature program on that front isn't exactly a sizzler.
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Inc PFE, one of the world's largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.
Wall St Veteran Names Worst Value Trap in the World
Lee and I have a list of stocks we love to hate, and one of Lee's picks is Pfizer (NYSE: PFE).
